Cardiotrophin-1 regulatory update

FDA and the European Commission granted Orphan Drug designation for Digna's cardiotrophin-1 to treat acute liver failure. The recombinant human CT-1 is in Phase I testing to treat ischemic and reperfusion injuries associated with liver transplant and liver resection due to tumors. Digna plans to start a Phase II trial in acute liver failure by year end 2012. ...